UF-Bred MicroPure Genomics Awarded Competitive NSF Grant
MicroPure Genomics Inc., a revolutionary sample prep technology company with deep University of Florida roots, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for nearly $1.3 million to conduct research and development on redefining front-end sample preparation for genomic analysis in research and healthcare.
TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (Pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, formed by CohBar and Morphogenesis, a UF startup, has announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA's lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).
Myosin Therapeutics Receives FDA Clearance To Initiate First-in-Human Trial of MT-125 in Glioblastoma
UF startup Myosin Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for MT-125.
Florida Venture Forum Announces Startups Selected to Present at 2025 Florida Early Stage Venture Conference
Oboro Labs, a UF startup, is among the companies selected to pitch at the 2025 Florida Early Stage Venture Conference, showcasing the innovative technologies emerging from UF’s entrepreneurial ecosystem.
Tech Tuesday: University of Florida Startup Is Changing How Students Connect With Classmates
In this week’s Tech Tuesday, UF Innovate host Bethany Gaffey introduces CourseLynx, a UF startup transforming how students connect on campus and in class.
Tech Tuesday: University of Florida Startup Aims To See How A.I. Can Be Used as a Teaching Tool
In this week’s Tech Tuesday, UF Innovate features Knowlify, a UF startup that’s transforming education with AI by instantly turning homework problems into personalized teaching videos.
Atsena Therapeutics Announces Positive Clinical Data From Part A of Phase I/II Trial Evaluating ATSN-201 Gene Therapy To Treat X-Linked Retinoschisis (XLRS)
UF startup Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a Phase I/II clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Tech Tuesday: University of Florida Startup Aims To Improve How Polymers Are Made
In this week’s Tech Tuesday, UF Innovate host Bethany Gaffey interviews Gregory Kis, CEO of Oboro Labs and winner of the Panelists’ Choice award in the established companies category at the spring GatorPitch Miami event.
Genascence Phase 1b DONATELLO Trial Evaluating Potential First-in-Class Gene Therapy for Knee Osteoarthritis (OA) Meets Primary Endpoint Showing GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
UF startup Genascence Corporation announced positive 12-month safety and biomarker results from the Phase 1b DONATELLO clinical trial evaluating GNSC-001, a potential first-in-class gene therapy blocking interleukin 1 (IL-1) for the treatment of knee osteoarthritis (OA).
Biotech Industry in Gainesville Is Booming
Gainesville's booming biotech industry, bolstered by UF Innovate's incubators and a supportive business environment, showcases the success of UF-affiliated startups and the city's commitment to innovation and entrepreneurship.
